Trial site
Centre Monticelli Paradis d'Ophtalmologie
Marseille, 13008, FranceNot linked to an institution yet
- 18running trials
- 7closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 27 trials
- Phase 2/33 trials
- Phase 41 trial
- Status
- Recruiting9 trials
- Active, not recruiting7 trials
- Completed7 trials
- Not yet recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche4 trials
- AbbVie3 trials
- Eyebiotech Limited2 trials
- 4d Molecular Therapeutics Inc.1 trial
- ACELYRIN Inc.1 trial
- and 14 more
Running trials
Recruiting
Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.
2026-526775-27-00· Phase 2· Laboratoires Kol· Source
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source
Active, not recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065· Phase 3· AbbVie· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Recruiting
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549· Phase 2· Galimedix Therapeutics Inc· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593· Phase 3· Belite Bio, Inc· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Recruiting
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
NCT04292080· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636· Phase 3· AbbVie· Source
Recruiting
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
2024-513983-24-00· Phase 4· Centre Hospitalier Universitaire De Dijon· Source
Active, not recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289· Phase 3· Hoffmann-La Roche· Source
Enrolling by invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801· Phase 2· AbbVie· Source
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error